Skip to content
PubMed This is a summary of 54 peer-reviewed journal articles Updated
Clinical Immunology · Activated PI3K Delta Syndrome Type 2

APDS2 (Activated PI3K Delta Syndrome Type 2): A Patient Guide

At a Glance

APDS2 is a rare PIK3R1-related immune disorder that can cause repeated infections while immune activity stays too high. Care focuses on replacing missing antibodies, using targeted medicines, and monitoring swollen lymph nodes and an enlarged spleen, autoimmune problems, and long-term lung damage.

APDS2, also known as PASLI-R1, is a rare genetic condition that fundamentally changes how the immune system responds to the world. It is caused by a specific error in the PIK3R1 gene, which provides instructions for a protein that normally acts as a regulator or “brake” for immune cell activity [1]. When this gene is altered, the immune system loses its ability to regulate itself correctly, leading to a state where certain pathways are constantly stuck in the “on” position [2]. This hyperactivity creates a unique medical paradox: the immune system is simultaneously overactive and underactive, leaving the body vulnerable to infections while also causing it to over-react in ways that can lead to internal swelling or inflammation [3].

The behavior of APDS2 is characterized by several core features that require careful, lifelong management. Because the immune system’s “on-switch” is hyperactive, white blood cells often mature too quickly and fail to become effective “soldiers” against germs, resulting in frequent and recurrent infections of the ears, sinuses, and lungs [4]. At the same time, this constant signaling causes immune cells to accumulate in the lymph nodes, spleen, and digestive tract, leading to persistent swelling (lymphoproliferation) and occasionally causing the immune system to mistakenly attack the body’s own healthy tissues (autoimmunity) [5][6]. While these symptoms can be challenging, the fact that APDS2 is now understood at a molecular level means that care involves a targeted effort to manage the immune system’s specific dysfunction, though it remains a condition with variable clinical severity [7].

Living with APDS2 effectively means focusing on a few critical priorities: protecting the lungs from long-term damage (bronchiectasis), monitoring the growth of lymphoid tissue, and utilizing treatments that address the specific manifestations of the disease. Modern medicine offers a range of options, from foundational therapies that replace missing antibodies to newer, targeted medications designed to specifically “dial down” the hyperactive pathway caused by the PIK3R1 variant [8]. It is important to note that these treatments modulate the dysregulated signaling or replace antibodies, but they do not correct the gene itself. Because the condition affects every person differently—even within the same family (variable expressivity)—care must be highly individualized and coordinated by a team of specialists who understand the complexity of this rare disorder [9][10].

While a diagnosis of APDS2 brings significant new information to process, it also brings a roadmap for the future. You are moving away from a period of unexplained illness and into a phase of proactive, informed management. By working closely with a multidisciplinary care team and remaining vigilant through regular monitoring, families can manage the risks of the condition. The discovery of the genetic cause of APDS2 has opened doors to therapies that provide a path toward better-targeted care [11][12].

Common questions in this guide

What is APDS2 and what causes it?
APDS2, also called PASLI-R1, is a rare genetic immune disorder caused by a change in the PIK3R1 gene. It can make the immune system less able to fight infections while also causing excessive immune activity, swelling of lymph tissues, and sometimes autoimmune problems.
What symptoms and health problems can APDS2 cause?
People with APDS2 may have repeated infections of the ears, sinuses, and lungs. The condition can also cause swollen lymph nodes, an enlarged spleen, swelling in the digestive tract, autoimmune problems, and long-term lung damage such as bronchiectasis.
How is APDS2 diagnosed, and why does genetic testing matter?
APDS2 is identified through genetic testing that finds a relevant change in the PIK3R1 gene, together with the person's immune and medical findings. A molecular diagnosis can help the care team choose more targeted monitoring and treatment than a general immune deficiency label may allow.
What treatments are used for APDS2?
Treatment may include antibody replacement therapy to help protect against infections and targeted medicines that reduce overactive immune signaling. These treatments manage the immune problem but do not correct the PIK3R1 gene change, so care is individualized and ongoing.
Why is lung monitoring important for people with APDS2?
Repeated respiratory infections can put the lungs at risk for long-term damage, including bronchiectasis. A personalized monitoring plan helps the care team watch lung health and identify problems even when there is no active infection.
Can APDS2 affect people differently?
Yes. APDS2 can vary in severity, even among members of the same family, a pattern known as variable expressivity. Monitoring and treatment are therefore tailored to each person's symptoms, immune findings, and genetic result.

Get notified when new evidence is published on immunodeficiency 132b.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (12)
  1. 1

    Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives.

    IJspeert H, Dalm VASH, van Zelm MC, Edwards ESJ

    Immunotherapy advances 2024; (4(1)):ltae009 doi:10.1093/immadv/ltae009.

    PMID: 39679264
  2. 2

    Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1.

    Dornan GL, Siempelkamp BD, Jenkins ML, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2017; (114(8)):1982-1987 doi:10.1073/pnas.1617244114.

    PMID: 28167755
  3. 3

    Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.

    Elkaim E, Neven B, Bruneau J, et al.

    The Journal of allergy and clinical immunology 2016; (138(1)):210-218.e9 doi:10.1016/j.jaci.2016.03.022.

    PMID: 27221134
  4. 4

    CD57 identifies T cells with functional senescence before terminal differentiation and relative telomere shortening in patients with activated PI3 kinase delta syndrome.

    Cura Daball P, Ventura Ferreira MS, Ammann S, et al.

    Immunology and cell biology 2018; (96(10)):1060-1071 doi:10.1111/imcb.12169.

    PMID: 29790605
  5. 5

    Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.

    Maccari ME, Abolhassani H, Aghamohammadi A, et al.

    Frontiers in immunology 2018; (9()):543 doi:10.3389/fimmu.2018.00543.

    PMID: 29599784
  6. 6

    Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient.

    Conti F, Catelli A, Cifaldi C, et al.

    Frontiers in pediatrics 2021; (9()):702546 doi:10.3389/fped.2021.702546.

    PMID: 34307262
  7. 7

    Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.

    Asano T, Okada S, Tsumura M, et al.

    Frontiers in immunology 2018; (9()):568 doi:10.3389/fimmu.2018.00568.

    PMID: 29675019
  8. 8

    A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.

    Rao VK, Webster S, Šedivá A, et al.

    Blood 2023; (141(9)):971-983 doi:10.1182/blood.2022018546.

    PMID: 36399712
  9. 9

    Clinical and immunological assessment of APDS2 with features of the SHORT syndrome related to a novel mutation in PIK3R1 with reduced penetrance.

    Szczawińska-Popłonyk A, Bernat-Sitarz K, Schwartzmann E, et al.

    Allergologia et immunopathologia 2022; (50(4)):1-9 doi:10.15586/aei.v50i4.510.

    PMID: 35789397
  10. 10

    Spanish Consensus on the Diagnosis and Management of Patients With Activated PI3K Delta Syndrome (APDS).

    Neth O, Alsina L, Rivière JG, et al.

    Journal of investigational allergology & clinical immunology 2025; (35(2)):87-102 doi:10.18176/jiaci.1059.

    PMID: 40028901
  11. 11

    Leniolisib: First Approval.

    Duggan S, Al-Salama ZT

    Drugs 2023; (83(10)):943-948 doi:10.1007/s40265-023-01895-4.

    PMID: 37256490
  12. 12

    Open-label extension study of leniolisib in activated PI3Kδ syndrome: Long-term efficacy and safety.

    Rao VK, Šedivá A, Dalm VASH, et al.

    Journal of human immunity 2027; (3(1)) doi:10.70962/jhi.20260040.

    PMID: 42873197

This APDS2 guide is for informational purposes and does not constitute medical advice. An immunologist and other members of your care team can interpret your PIK3R1 result and recommend monitoring and treatment for your situation.